RNA - Neuromuscular Focused-Avidity Biosciences Has 'Complete Package' - Analyst Predicts Stellar 142% Stock Surge | Benzinga
Cantor Fitzgerald has initiated coverage on Avidity Biosciences Inc (NASDAQ:RNA), noting the company has the complete package, including a strong management team, a proven platform, a robust pipeline, and a blockbuster product in deldesiran (formerly AOC 1001) for Myotonic dystrophy type 1 (DM1).
The analyst reports that Avidity has accumulated extensive biomarker and clinical data, significantly reducing the risks associated with their upcoming Phase 3 study.
Additionally, Dyne Therapeutics Inc (NASDAQ:DYN), a competitor trailing by approximately 12 months, is also generating similar data using a comparable approach, thereby offering further validation.
Also Read: Avidity Biosciences Says Lead Program Shows Reversal Of Disease Progression In Neuromuscular Disease.
Despite the potential variability in biomarker data obtained ...